Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan

Journal of Infection and Chemotherapy

Volumn 19, Issue 2, 2013, Pages 291-298

  Yamamoto, Yoshihiro ^a,b   Izumikawa, Koichi ^a   Morinaga, Yoshitomo ^c   Nakamura, Shigeki ^a   Kurihara, Shintaro ^c   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Tsukamoto, Misuzu ^c   Kakeya, Hiroshi ^a   Yanagihara, Katsunori ^c   Yasuoka, Akira ^c   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antimicrobials; Healthcare associated pneumonia; Meropenem; Nursing and healthcare associated pneumonia; Piperacillin tazobactam

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BACTERIUM ISOLATION; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEALTH CARE ASSOCIATED PNEUMONIA; HEMATURIA; HUMAN; HYPERKALEMIA; JAPAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; MULTICENTER STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL PNEUMONIA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84880700595     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0552-6     Document Type: Article

References (21)

1. Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/toukei/ saikin/hw/jinkou/geppo/nengai11/index.html. Accessed 5 June 2012 (in Japanese).
2. The Japanese Respiratory Society. Guidelines for the management of nursing and health care-associated pneumonia. Tokyo: The Japanese Respiratory Society; 2011 (in Japanese).
3. The American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health care-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
4. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854-62.
5. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568-73.
6. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135:633-40.
7. Teramoto S, Kawashima M, Komiya K, Shoji S. Health-care-associated pneumonia is primarily due to aspiration pneumonia. Chest. 2009;136:1702-3.
8. Gaynes R. Health-care associated bloodstream infections: a change in thinking. Ann Intern Med. 2002;137:850-1.
9. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31:S131-8.
10. Kett DH, Cano E, Quartin AA, Manqino JE, Zervos MJ, Peyrani P, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis. 2011;11:181-9.
11. Brito V, Niderman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis. 2009;22:316-25.
12. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
13. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the committee for respiratory system, Japan Society of Chemotherapy. J Infect Chemother. 1999;5:110-23.
14. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother. 1998;42:2966-72.
15. Joshi M, Bernstein J, Solomkin J, Wester BA, Kuye O. Piperacillin/ tazobactam Nosocomial Pneumoniae Study Group: piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. J Antimicrob Chemother. 1999;43:389-97.
16. Joshi M, Metzler M, McCarthy M, Olvey S, Kassira W, Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumoniae. Respir Med. 2006;100:1554-65.
17. Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaquer R, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167:1393-9.
18. Venditti M, Falcone M, Corrao S, Licata G, Serra P, Study Group of Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19-26.
19. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006;130:787-93.
20. ® package insert. Revised in September 2012.
21. ® package insert. Revised in January 2012.